Meeting
2023 ASCO Annual Meeting
Prostate-specific membrane antigen (PSMA) expression in patients with metastatic triple negative breast cancer: Initial results of the PRISMA study.
Authors
Guilherme Nader Marta
Academic Trials Promoting Team, Institut Jules Bordet and l’Université Libre de Bruxelles (U.L.B), Brussels, Belgium
Guilherme Nader Marta , Zena Wimana , Loubna Taraji , Gabriela Critchi , Philippe Georges Aftimos , Martine J. Piccart-Gebhart , Patrick Flamen , Geraldine Gebhart
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1025)
DOI
10.1200/JCO.2023.41.16_suppl.1025
Abstract #
1025
Poster Bd #
246
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate-resistant prostate cancer.
First Author: Geoffrey Johnson
Poster
2023 ASCO Annual Meeting
177Lu-PSMA radioligand therapy for recurrent/metastatic (R/M) salivary gland cancer (SGC) patients: A phase II pilot study.
First Author: Carla M.L.- Van Herpen
Poster
2023 ASCO Annual Meeting
Negative estrogen receptor expression assessed by 18F-FES PET in metastatic breast cancer with ER-positive primary tumor.
First Author: Biyun Wang
Poster
2023 ASCO Annual Meeting
Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) disease extent and overall survival (OS) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC): An international multicenter retrospective study.
First Author: Boris A. Hadaschik